Reduce Sun Pharma, target Rs 482: Elara Capital
Reduce Sun Pharmaceutical Industries Ltd. at a price target of Rs 482.0 .

Sun Pharmaceutical Industries Ltd., incorporated in 1993, is a largecap company with a market cap of Rs 134278.20 crore.
Investment rationale by Elara Capital
Halol clearance provides comfort on Sun’s achievement of guidance of early double-digit revenue growth in FY19. Focus would shift back to earnings quality and ramp-up in the specialty business. The stock has seen a 10% run-up over past three trading days post FDA status of VAI on the Halol facility. At the CMP, the stock is trading at rich valuations of 25x FY20E P/E and factors in the Halol clearance, in our view. We retain Reduce with a TP of INR 482 based on 22x FY20E P/E.
Download ET Markets APP